Aseel H. Alzibdeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aseel H. Alzibdeh has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Muna Al Maslamani
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
2 shared publications Abdul-Badi Abou-Samra
Corporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar
1 shared publicationAbdullatif Al-Khal
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
1 shared publication- Abdulsalam Saif Ibrahim
Medical Intensive Care Unit, Hamad General Hospital, Doha, Qatar; Department of Medicine, Weill Cornell Medical College, Doha, Qatar
1 shared publication - Abdurrahmaan Elbuzidi
Department of Medical Intensive Care, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar
1 shared publication - Adeel Ajwad Butt
Department of Population Health Sciences, Weill Cornell Medicine, Cornell University , New York, New York
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Transplant Infectious Disease
The Direction of the Clostridioides difficile –Gastrointestinal GVHD Relationship After Allogenic Hematopoietic Cell Transplantation: A Time‐Dependent CIBMTR Analysis
Background: Clostridioides difficile infection (CDI) and gastrointestinal acute graft‐versus‐host disease (GI‐GVHD) frequently co‐occur after allogeneic hematopoietic cell transplantation (allo‐HCT), and a bidirectional relationship has been proposed. The prior CIBMTR analysis associated antecedent GI‐GVHD with CDI but modeled GI‐GVHD as a fixed exposure and could not test whether CDI predicts subsequent GI‐GVHD. Methods: We analyzed a publicly available CIBMTR dataset of patients undergoing first allo‐HCT for AML, ALL, or MDS (2013–2018), each complication was modeled as a time‐dependent exposure using cause‐specific Cox regression, with death and relapse treated as competing events, adjusting for donor type, disease, conditioning intensity, and (reverse direction) GVHD prophylaxis type. Sensitivity analyses included restriction to adults and exclusion of CDI diagnosed before post‐transplant cyclophosphamide PTCy. Results: CDI within 100 days occurred in 777 patients (11%). CDI did not predict subsequent GI‐GVHD (HR 1.15; 95% CI 0.90–1.48; p = 0.26). GI‐GVHD predicted subsequent CDI (HR 1.54; 95% CI 1.08–2.19; p = 0.016), unchanged after adjustment for prophylaxis type and stronger in adults (HR 1.73; 95% CI 1.18–2.55). An apparent PTCy–CDI association (HR 1.38; 95% CI 1.08–1.75; p = 0.009), was driven by CDI with onset by Day 4, before PTCy, and was no longer significant once excluded (HR 1.11; 95% CI 0.80–1.52). Conclusions: When event timing and competing risks are respected, the GI‐GVHD predicts subsequent CDI whereas the reverse is not observed. GI‐GVHD identifies patients at elevated risk who are candidates for heightened surveillance. The disappearance of the PTCy signal once drug timing was respected illustrates how event ordering can misattribute risk.
- 29 October 2026
- Published by Wiley in Transplant Infectious Disease
Open AccessThe Direction of the Clostridioides difficile –Gastrointestinal GVHD Relationship After Allogenic Hematopoietic Cell Transplantation: A Time‐Dependent CIBMTR Analysis
Background: Clostridioides difficile infection (CDI) and gastrointestinal acute graft‐versus‐host disease (GI‐GVHD) frequently co‐occur after allogeneic hematopoietic cell transplantation (allo‐HCT), and a bidirectional relationship has been proposed. The prior CIBMTR analysis associated antecedent GI‐GVHD with CDI but modeled GI‐GVHD as a fixed exposure and could not test whether CDI predicts subsequent GI‐GVHD. Methods: We analyzed a publicly available CIBMTR dataset of patients undergoing first allo‐HCT for AML, ALL, or MDS (2013–2018), each complication was modeled as a time‐dependent exposure using cause‐specific Cox regression, with death and relapse treated as competing events, adjusting for donor type, disease, conditioning intensity, and (reverse direction) GVHD prophylaxis type. Sensitivity analyses included restriction to adults and exclusion of CDI diagnosed before post‐transplant cyclophosphamide PTCy. Results: CDI within 100 days occurred in 777 patients (11%). CDI did not predict subsequent GI‐GVHD (HR 1.15; 95% CI 0.90–1.48; p = 0.26). GI‐GVHD predicted subsequent CDI (HR 1.54; 95% CI 1.08–2.19; p = 0.016), unchanged after adjustment for prophylaxis type and stronger in adults (HR 1.73; 95% CI 1.18–2.55). An apparent PTCy–CDI association (HR 1.38; 95% CI 1.08–1.75; p = 0.009), was driven by CDI with onset by Day 4, before PTCy, and was no longer significant once excluded (HR 1.11; 95% CI 0.80–1.52). Conclusions: When event timing and competing risks are respected, the GI‐GVHD predicts subsequent CDI whereas the reverse is not observed. GI‐GVHD identifies patients at elevated risk who are candidates for heightened surveillance. The disappearance of the PTCy signal once drug timing was respected illustrates how event ordering can misattribute risk.
- Open Access
- 9 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (6) , 653
Infectious Complications in Adults Receiving Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis of Nosocomial and Bloodstream Infection, Prevalence, Risk Factors, and Clinical Outcomes
Background/Objectives: Reported infection rates during extracorporeal membrane oxygenation (ECMO) vary widely, partly because case definitions are applied inconsistently. We synthesized the prevalence and prognostic association of nosocomial and bloodstream infection (BSI) acquired during adult ECMO. Methods: PubMed/MEDLINE, Embase, Scopus and CENTRAL were searched through December 2025 for observational studies of at least 10 adults on ECMO with an explicit infection definition. We classified case definitions by the criteria actually applied. We pooled crude mortality odds ratios (ORs) and patient-level BSI prevalence in studies applying laboratory-confirmed criteria, assessed risk of bias with ROBINS-I and the JBI checklist, and rated certainty with GRADE. Results: Forty-seven reports (46 cohorts; 11,573 patients) were included. Pooled BSI prevalence was 25.8% (95% CI 17.3–36.5%; 7 studies, 1193 patients), 18.2% in pre-pandemic and 39.2% in COVID-19 cohorts (post hoc). Infection was associated with higher crude odds of death (OR 1.65, 1.33–2.04; prediction interval 0.95–2.85; 24 studies), but analyses modeling infection as time-varying were inconsistent, including no association in a multistate model (adjusted hazard ratio 1.00, 0.79–1.26), and small-study effects were suggested. Certainty was very low for both outcomes. Conclusions: Roughly one in four adults on ECMO developed laboratory-confirmed BSI, more often in COVID-19 cohorts. Whether infection acquired on ECMO increases mortality remains uncertain.
- 9 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (6) , 653
Open AccessInfectious Complications in Adults Receiving Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis of Nosocomial and Bloodstream Infection, Prevalence, Risk Factors, and Clinical Outcomes
Background/Objectives: Reported infection rates during extracorporeal membrane oxygenation (ECMO) vary widely, partly because case definitions are applied inconsistently. We synthesized the prevalence and prognostic association of nosocomial and bloodstream infection (BSI) acquired during adult ECMO. Methods: PubMed/MEDLINE, Embase, Scopus and CENTRAL were searched through December 2025 for observational studies of at least 10 adults on ECMO with an explicit infection definition. We classified case definitions by the criteria actually applied. We pooled crude mortality odds ratios (ORs) and patient-level BSI prevalence in studies applying laboratory-confirmed criteria, assessed risk of bias with ROBINS-I and the JBI checklist, and rated certainty with GRADE. Results: Forty-seven reports (46 cohorts; 11,573 patients) were included. Pooled BSI prevalence was 25.8% (95% CI 17.3–36.5%; 7 studies, 1193 patients), 18.2% in pre-pandemic and 39.2% in COVID-19 cohorts (post hoc). Infection was associated with higher crude odds of death (OR 1.65, 1.33–2.04; prediction interval 0.95–2.85; 24 studies), but analyses modeling infection as time-varying were inconsistent, including no association in a multistate model (adjusted hazard ratio 1.00, 0.79–1.26), and small-study effects were suggested. Certainty was very low for both outcomes. Conclusions: Roughly one in four adults on ECMO developed laboratory-confirmed BSI, more often in COVID-19 cohorts. Whether infection acquired on ECMO increases mortality remains uncertain.
- Open Access
- 14 April 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 132, 4-8
Immediate and contributory causes of death in patients hospitalized with COVID-19
- 14 April 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 132, 4-8
Open AccessImmediate and contributory causes of death in patients hospitalized with COVID-19
- Open Access
- 21 January 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (3) , 1353-1357
Disseminated tuberculosis masquerading as Tolosa-Hunt syndrome in initial presentation: A case report with literature review
- 21 January 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (3) , 1353-1357
Open AccessDisseminated tuberculosis masquerading as Tolosa-Hunt syndrome in initial presentation: A case report with literature review